The link between acetaminophen leverage during pregnancy and neurodevelopmental disorders in children, such as attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder, remains scientifically inconclusive, according to a new study published in JAMA Pediatrics. This research adds to the ongoing debate surrounding the safety of common pain relievers during pregnancy, a concern for many expectant mothers.
Researchers analyzed data from over 2 million singleton births in Taiwan between 2004 and 2015, making it one of the largest studies to investigate this potential association. The study found that approximately 48.3% of mothers received at least two prescriptions for acetaminophen during their pregnancy.
Initial analysis revealed a statistical association between acetaminophen use during pregnancy and an increased risk of ADHD or autism in children. The association appeared stronger among mothers who used the medication frequently or at higher doses during pregnancy. However, this initial link largely disappeared when researchers employed a more rigorous analysis comparing siblings within the same families.
This sibling comparison method aims to reduce the influence of shared genetic and environmental factors. The researchers noted that the initial association may be due to other unmeasured factors, such as the mother’s genetic background or pre-existing health conditions.
Further, more complex analyses yielded conflicting results. When the older sibling in a family was exposed to acetaminophen during pregnancy, a positive association emerged, suggesting an increased risk of ADHD and autism. Conversely, when the younger sibling was exposed, a negative association appeared, indicating a potential decrease in risk. Researchers believe this significant variation in findings suggests potential statistical or methodological biases in the sibling analysis, making interpretation more challenging.
Study Design Challenges
The study highlights challenges inherent in sibling comparison studies, including reduced statistical power and the influence of time-varying factors or birth order. These types of analyses can sometimes amplify errors or introduce new biases into the data.
Researchers suggest that unmeasured confounding factors related to acetaminophen use during pregnancy could explain the discrepancies. For example, the mother’s overall health status or the underlying conditions necessitating medication use may also be linked to a child’s risk of neurodevelopmental disorders, making it difficult to isolate the drug’s effect.
The study relied on prescription records, which may not fully reflect total acetaminophen use, as the medication is also readily available over the counter. However, Taiwan’s healthcare system encourages obtaining medications via prescription, making the data relatively representative of actual usage.
The researchers emphasize that the findings do not allow for a definitive conclusion regarding the relationship between acetaminophen use during pregnancy and neurodevelopmental disorders in children. The substantial variation in results across different analytical methods indicates that unaddressed sources of bias remain in current studies.
Looking ahead, researchers call for future studies employing more precise methods for measuring drug exposure and diagnosing neurological disorders, while also accounting for genetic and environmental factors. They stress that a more comprehensive understanding of this relationship requires advanced research designs integrating clinical, genetic, and behavioral data.
The researchers underscore the scientific complexity of studying the effects of medications during pregnancy on children’s brain development, and maintain that the relationship between acetaminophen and neurodevelopmental disorders remains an open question for ongoing scientific investigation.
